Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial
about
Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumorSunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectivesCurrent management and prognostic features for gastrointestinal stromal tumor (GIST)Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial.Sunitinib malate for the treatment of solid tumours: a review of current clinical data.Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylateMolecular pathology of sarcomas: concepts and clinical implicationsComparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.Imatinib: a breakthrough of targeted therapy in cancer.Evaluation of self-reported progression and correlation of imatinib dose to survival in patients with metastatic gastrointestinal stromal tumors: an open cohort studyDramatic regression and bleeding of a duodenal GIST during preoperative imatinib therapy: case report and review.Anti-angiogenesis therapies: their potential in cancer managementProteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy.Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.Tumor volume as an alternative response measurement for imatinib treated GIST patients.Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate.Management of resectable gastrointestinal stromal tumor.The role of oncogenes in gastrointestinal cancer.HER4 is a novel prognostic biomarker in gastrointestinal stromal tumor specifically originated from stomach.Somatostatin receptors in gastrointestinal stromal tumors: new prognostic biomarker and potential therapeutic strategyCirculating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failureImatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal.A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.Improved detection of KIT exon 11 duplications in formalin-fixed, paraffin-embedded gastrointestinal stromal tumors.Relationship of preoperative neutrophil lymphocyte ratio with prognosis in gastrointestinal stromal tumors.Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.Management of a Gastrobronchial Fistula Connected to the Skin in a Giant Extragastric Stromal Tumor.Advances in the surgical management of gastrointestinal stromal tumorRecent advances and novel agents for gastrointestinal stromal tumor (GIST)Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients.Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case-based approach.Imatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs.A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumoursBlood neutrophil-to-lymphocyte ratio is prognostic in gastrointestinal stromal tumor.Drug repurposing for gastrointestinal stromal tumor.Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia.
P2860
Q27690634-353AAD3E-F1C3-4A13-9F90-9A7D47A35C1BQ27851455-CCF9EADB-5D80-48EE-8648-A6FD204FB594Q28069560-13417C6B-11DB-49A4-8684-5E8679D01ABCQ28391684-63B6D75B-A5B3-4E8B-8A0A-5D1042991C41Q30245586-616DB3C4-A6AF-4CEF-8C7C-F5156FB36526Q30485073-C99C3BDA-FF64-4C26-8C08-F2BCC5EF3AE6Q31037756-93E9F2DA-191B-414E-9165-3369BD84C945Q33392955-E8DD8D56-69EC-454F-9284-E60CFD9D278DQ33666010-640165F6-9CCD-4055-AD66-B5407714CE3BQ33688157-861D4B84-F161-4264-B6CB-DD7BC30A0F35Q33710999-A59D79C4-F958-414A-A1F3-E097D57FEAB4Q33747261-9C9E30A0-A210-4F5A-A767-E39AF995594BQ33756542-52A08C7E-07B8-47F5-8BE9-464FEEEB4964Q33931063-51A14FB0-A69E-452C-A49C-03BB3097AE63Q33956056-19972B64-FC8C-4330-95F7-DACAD52EC9DCQ34029127-32821267-7185-4A65-A08B-A9D48C3BF6BDQ34050275-A0EA4FB2-D374-42B0-A2BB-7D983DED03E4Q34469701-AAD93569-3A77-4431-AFD6-6F6E39977DF1Q34596126-4E7EB561-CECB-4891-A48F-6AC5E7460259Q34604924-B86293A1-8C70-431A-8239-85367D813A39Q34616409-F97235B9-F5D4-4B8A-AB11-B9E2F2124DC2Q34704954-2E3FFDDF-94FB-4BB5-AD79-4E73662D261AQ34978826-23D2A482-AC83-4240-AD1C-5C717B3E6288Q35001643-5D527226-451D-402A-8349-8954E58B5179Q35026332-F0EA5B7B-BF7E-4C3A-9D11-002C5FEC296BQ35089528-536DDCDE-9C6F-4763-B846-DE7FB196508DQ35789573-A70E6D87-E968-4522-9C1D-124F98E96C9FQ35799223-B74B9076-801C-40E1-A131-6FEDC2A5C09BQ35895558-6EBC366D-343F-46BC-A27C-7F5FD0B2676CQ35935532-8B25A381-842B-4ACA-ABB6-4643A5ACB064Q36045267-5768FD59-F463-4590-AC62-7C46D396AE9EQ36118178-FF6A891F-7221-4416-8AE9-C9E9FA749838Q36173335-26CBC753-D548-4271-A362-F4564E82D0FCQ36412696-50DF0BA7-3AE6-4567-B3B4-6869204CA195Q36491906-E716A9E1-F1D1-420D-858F-6EF9EC4AAAB1Q36563238-69044D0B-256B-49F8-962B-9889342CBE21Q36696431-D8EF0A9E-D3E6-4CBC-A416-E4A70D90A15FQ36979386-441EED7B-6469-4BCF-8DB3-4CD4B48D5FE3Q37001194-C11DBCC6-D219-4811-AC17-33BBE5E34F25Q37115871-B6A4F725-7AF5-40C5-A067-FF4078CCB699
P2860
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Initial and late resistance to ...... alasian Gastrointestinal Trial
@en
Initial and late resistance to ...... alasian Gastrointestinal Trial
@nl
type
label
Initial and late resistance to ...... alasian Gastrointestinal Trial
@en
Initial and late resistance to ...... alasian Gastrointestinal Trial
@nl
prefLabel
Initial and late resistance to ...... alasian Gastrointestinal Trial
@en
Initial and late resistance to ...... alasian Gastrointestinal Trial
@nl
P2093
P50
P356
P1476
Initial and late resistance to ...... alasian Gastrointestinal Trial
@en
P2093
Allan T van Oosterom
David Goldstein
Ian R Judson
Isabelle Ray-Coquard
Jaap Verweij
Marcus Schlemmer
Martine Van Glabbeke
Michelle Brown
Pancras C W Hogendoorn
Peter Hohenberger
P304
P356
10.1200/JCO.2005.11.601
P407
P577
2005-08-01T00:00:00Z